Desonide gel - Dow Pharmaceutical Sciences/SkinMedica

Drug Profile

Desonide gel - Dow Pharmaceutical Sciences/SkinMedica

Alternative Names: Desonate; Desonide hydrogel

Latest Information Update: 21 Dec 2012

Price : $50

At a glance

  • Originator Dow Pharmaceutical Sciences; SkinMedica
  • Class Anti-inflammatories; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Atopic dermatitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 19 Dec 2012 SkinMedica has been acquired by Allergan
  • 04 Sep 2009 Intendis signs agreement to acquire desonide gel from SkinMedica
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top